News & Events
Seres Therapeutics to Present at Jefferies Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jun. 2, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff , President and Chief Executive Officer of Seres Therapeutics , will provide a corporate presentation at the Jefferies Healthcare…
Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™ (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–May 30, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that the Company has received a $125 million milestone payment from Nestlé Health Science related to the U.S.…
Interim report January–March 2023 (opens in a new tab)
OSLO, NORWAY, May 25, 2023 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the first quarter of 2023. The interim report is available as an attached file to this release and on the Company’s website (www.genetic-analysis.com). Below is a summary of the report. Ronny Hermansen, CEO …
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates (opens in a new tab)
– VOWST ™ microbiota-based therapeutic approved for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI; product availability expected in June – – New SER-155 Phase 1b Cohort 1 clinical data show favorable tolerability, successful drug…
Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome (opens in a new tab)
– Tolerability profile observed supports continued development in Cohort 2, with no treatment attributed serious adverse events – – Reduction in incidences of microbiome pathogen domination provides support for intended SER-155 clinical activity – –SER-155 Phase 1b placebo-controlled Cohort 2 data…
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting (opens in a new tab)
– Data from Phase 3 open-label single-arm study of VOWST found nearly 95% of individuals with a clinical response at 8 weeks remained free of CDI through Week 24, regardless of number of prior C. difficile infections (CDI) – – Results from ECOSPOR IV add to data from ECOSPOR III Phase 3 study…
Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week (opens in a new tab)
VE303 receives Fast Track designation for prevention of recurrent C. difficile infection ahead of global pivotal Phase 3 study Exploratory analyses from the VE303 Phase 2 CONSORTIUM study identify statistically significant relationships between VE303 bacterial species and multiple parameters that provide further mechan…
Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023 (opens in a new tab)
– Company to report initial SER-155 Phase 1b safety and pharmacology results from study Cohort 1 – CAMBRIDGE, Mass. –(BUSINESS WIRE)–May 5, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and…
Seres Therapeutics Announces $250 Million Debt Financing with Oaktree (opens in a new tab)
– Company to receive proceeds of $110 million upon closing of the agreement – – Financing to support commercial launch of VOWST™ and fund pipeline development – CAMBRIDGE, Mass. –(BUSINESS WIRE)–Apr. 27, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company,…
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI (opens in a new tab)
– First and only FDA-approved orally administered microbiota-based therapeutic, validating Seres’ microbiome platform – – Phase 3 ECOSPOR III study demonstrated that 88% of treated individuals were recurrence-free at 8 weeks – – Opportunity to address prevention of recurrence of C.…
Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies (opens in a new tab)
Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin by 3Q 2023 Funds will also support Phase 2 study of VE202 for ulcerative colitis, to begin in 2Q 2023 Syndicate led by new investors AXA IM Alts and The AMR Action Fund along with existing investors Bill & Melinda Gates …
Bacthera Joins Microbiome Therapeutics Innovation Group (opens in a new tab)
WASHINGTON, April 24, 2023 /PRNewswire/ — The Microbiome Therapeutics Innovation Group (MTIG) today […]…
Publication of Genetic Analysis’ 2022 Annual Report (opens in a new tab)
(Oslo, April 20, 2023) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the Annual Report for the financial year of 2022. The Annual Report is available as an attached file to this release and on the Company’s website (www.genetic-analysis.com). For further information, please contact: Ronny Hermansen, CEO …
Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID (opens in a new tab)
JAMA publication includes in-depth safety and efficacy results from successful Phase 2 study of VE303 Additional analyses support a relationship between VE303 exposure and clinical response via enhanced bacterial colonization, in addition to new evidence of inflammation modulation in treated patients CAMBRIDGE, MA, Apr…
Genetic Analysis presents at Mangold Insight’s Investor Day (opens in a new tab)
OSLO, NORWAY, March 17, 2023 – Genetic Analysis (“GA”) will attend Mangold Insight’s Investor Day next Wednesday, 22 March 2023. Ronny Hermansen, CEO, and Kari Furu, Head of Product and Business Development, will present the company, the booming microbiome market, and the global potential and recognition of the GA-map®…
Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Mar. 9, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff , President and Chief Executive Officer of Seres Therapeutics , will provide a corporate presentation at the Oppenheimer 33rd Annual…
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (opens in a new tab)
– SER-109 Biologics License Application (BLA) under review with U.S. Food and Drug Administration (FDA) with target action date of April 26, 2023 under Prescription Drug User Fee Act (PDUFA) – – Anticipate SER-109 commercial launch soon after potential FDA approval decision – – SER-155 Phase 1b…
Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Feb. 28, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 7, 2023 at 8:30 a.m. ET to discuss fourth quarter and full year 2022…
Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Feb. 27, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff , President and Chief Executive Officer of Seres Therapeutics , will participate in a panel discussion at the Cowen 43rd Annual…
Year-end report January – December 2022 (opens in a new tab)
The post Year-end report January – December 2022 appeared first on Genetic Analysis.…